John M. Dineen - Net Worth and Insider Trading

John M. Dineen Net Worth

The estimated net worth of John M. Dineen is at least $900,269 dollars as of 2024-12-15. John M. Dineen is the Director of Syneos Health Inc and owns about 17,426 shares of Syneos Health Inc (SYNH) stock worth over $748,969. John M. Dineen is also the Director of Merrimack Pharmaceuticals Inc and owns about 10,000 shares of Merrimack Pharmaceuticals Inc (MACK) stock worth over $151,300. Details can be seen in John M. Dineen's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that John M. Dineen has not made any transactions after 2020-07-06 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

GuruFocus Premium Membership
30 Years of Financial Data
Unlimited Filters in All-in-One Stock Screener
Earnings Calls & Stock Analysis
Customizable Stock Dashboard
Real-Time Insider Trading Alerts
8,000+ Institutional Investors’ 13F Holdings
Excel & Google Sheets Integration
Quick Customer Support
And Much More...

Transaction Summary of John M. Dineen

To

John M. Dineen Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, John M. Dineen owns 4 companies in total, including Syneos Health Inc (SYNH) , Cognizant Technology Solutions Corp (CTSH) , and Merrimack Pharmaceuticals Inc (MACK) among others .

Click here to see the complete history of John M. Dineen’s form 4 insider trades.

Insider Ownership Summary of John M. Dineen

Ticker Comapny Transaction Date Type of Owner
SYNH Syneos Health Inc 2020-07-06 director
CTSH Cognizant Technology Solutions Corp 2021-06-01 director
MACK Merrimack Pharmaceuticals Inc 2015-08-12 director
LIMIT LIMIT 2023-08-24 director

John M. Dineen Latest Holdings Summary

John M. Dineen currently owns a total of 2 stocks. Among these stocks, John M. Dineen owns 17,426 shares of Syneos Health Inc (SYNH) as of July 6, 2020, with a value of $748,969 and a weighting of 83.19%. John M. Dineen also owns 10,000 shares of Merrimack Pharmaceuticals Inc (MACK) as of August 12, 2015, with a value of $151,300 and a weighting of 16.81%.

Latest Holdings of John M. Dineen

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
SYNH Syneos Health Inc 2020-07-06 17,426 42.98 748,969
MACK Merrimack Pharmaceuticals Inc 2015-08-12 10,000 15.13 151,300

Holding Weightings of John M. Dineen


John M. Dineen Form 4 Trading Tracker

According to the SEC Form 4 filings, John M. Dineen has made a total of 1 transactions in Syneos Health Inc (SYNH) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Syneos Health Inc is the acquisition of 8,691 shares on July 6, 2020, which cost John M. Dineen around $513,725.

According to the SEC Form 4 filings, John M. Dineen has made a total of 0 transactions in Merrimack Pharmaceuticals Inc (MACK) over the past 5 years. The most-recent trade in Merrimack Pharmaceuticals Inc is the acquisition of 10,000 shares on August 12, 2015, which cost John M. Dineen around $1 Million.

Insider Trading History of John M. Dineen

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

John M. Dineen Trading Performance

GuruFocus tracks the stock performance after each of John M. Dineen's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by John M. Dineen is -9.28%. GuruFocus also compares John M. Dineen's trading performance to market benchmark return within the same time period. The performance of stocks bought by John M. Dineen within 3 months outperforms 0 times out of 2 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how John M. Dineen's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of John M. Dineen

Average Return

LIMIT
Average return per transaction

Outperforming Transactions

LIMIT
1 out of 2 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) 5.15 LIMIT LIMIT LIMIT LIMIT LIMIT
Relative Return to S&P 500(%) 5.48 LIMIT LIMIT LIMIT LIMIT LIMIT

John M. Dineen Ownership Network

Ownership Network List of John M. Dineen

No Data

Ownership Network Relation of John M. Dineen

Insider Network Chart

John M. Dineen Owned Company Details

What does Syneos Health Inc do?

Who are the key executives at Syneos Health Inc?

John M. Dineen is the director of Syneos Health Inc. Other key executives at Syneos Health Inc include Chief Financial Officer Michael J. Bonello , See remarks Stanford Rudnick , and Chief Business Officer Christian Tucat .

Syneos Health Inc (SYNH) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Syneos Health Inc (SYNH) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Syneos Health Inc (SYNH) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Syneos Health Inc (SYNH)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Syneos Health Inc Insider Transactions

No Available Data

John M. Dineen Mailing Address

Above is the net worth, insider trading, and ownership report for John M. Dineen. You might contact John M. Dineen via mailing address: Merrimack Pharmaceuticals, Inc., One Kendall Square, Suite B7201, Cambridge Ma 02139.